Experimental and Clinical Study of a New Permanent Myocardial Atrial Sutureless Pacing Lead

Abstract

A new permanent lead has been developed for atrial epicardial use. Early clinical evaluation (26 human implants) following thorough canine studies indicates that the new lead is safe, effective, and reliable. Canine thresholds and P-wave amplitudes as a function of implant time are similar to those of transvenous atrial "J" leads. Human thresholds at implant are higher than canine, but change less with time. Implant and acute repositioning were found to be easy. There have been no lead-related operations.

Effectiveness of epicardial atrial pacing using a bipolar steroid-eluting endocardial lead with active fixation in an experimental model

“…In the same direction, the performance of atrial sensing was similar with previous studies 11,12,14 . The already initially good sensing values (5 mV) showed a decrease in the immediate postoperative but afterwards remained stable during the whole follow-up period.…”

“…After three to four post-implantation weeks, the global inflammatory response has essentially resolved and thresholds may subsequently decrease or remain stable, depending on the intensity of the foreign body response at the electrode-tissue interface 6,11,13 . Bognolo et al 14 compared the performance of three types of leads (two epicardial and one endocardial) in six dogs.…”